Novo Nordisk and Evotec LAB eN2 – Johns Hopkins University Collaboration
Supports JHU faculty research to develop novel therapies and tools for cardio-metabolic diseases and rare blood disorders, advancing discoveries toward IND-ready clinical candidates.
Funder: Johns Hopkins University
Due Dates: Rolling (Project Concept Forms)
Funding Amounts: Up to $4,000,000 per award; funding supports multi-stage projects to IND-ready candidates.
Summary: Supports JHU faculty research to advance novel therapies for cardio-metabolic diseases and rare blood disorders in collaboration with Novo Nordisk and Evotec.
Key Information: Only JHU faculty are eligible; initial submission is a Project Concept Form.
Description
This internal funding opportunity, a collaboration between Johns Hopkins University, Novo Nordisk, and Evotec (LAB eN2), aims to accelerate the translation of academic discoveries into IND-ready therapeutic candidates. The program targets research that advances new targets, provides disease biology insights, and develops innovative research tools for cardio-metabolic diseases and rare blood disorders. Areas of interest include diabetes, obesity, chronic and rare diseases, technology platforms, and modality-agnostic approaches. The collaboration is designed to bridge academic research and industry expertise, moving promising discoveries toward clinical application.
